Clinical Trial Update: Gene Expression in Renal Transplant Patients With Field Actinic Keratosis Undergoing Metvix® Photodynamic Therapy (PDT) [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating gene expression in renal transplant patients with actinic keratosis treated with Metvix photodynamic therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratosis

Drugs mentioned

• Metvix (methyl aminolevulinate)

Snippet

Sponsor: Galderma R&D | Conditions: Actinic Keratosis | Phase 4 | Status: COMPLETED | Results posted: 2021-05-26